Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Chiara Deiana
Observed names:
C. Deiana,
Deiana, Chiara
Institutions:
IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola,
University of Bologna
Observed institutions:
University of Trieste,
IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola,
Sapienza University of Rome,
University of Bologna
ORCID:
0000-0002-0652-5049
Observed ORCID:
0000-0002-0652-5049
OpenAlex ID:
A5076642857
The Landscape of Immunotherapy in Advanced NSCLC: Driving Beyond PD-1/PD-L1 Inhibitors (CTLA-4, LAG3, IDO, OX40, TIGIT, Vaccines)
2021
·
Andrea De Giglio
, Alessandro Di Federico
, et al.
·
Current Oncology Reports
·
95
PDF
Pharmacological treatment with mirtazapine rescues cortical atrophy and respiratory deficits in MeCP2 null mice
2016
·
Tamara Bittolo
, Carlo Antonio Raminelli
, et al.
·
Scientific Reports
·
63
Clinical Utility and Application of Liquid Biopsy Genotyping in Lung Cancer: A Comprehensive Review
2023
·
Maria Concetta Nigro
, Paola Valeria Marchese
, et al.
·
Lung Cancer Targets and Therapy
·
25
PDF
Bone-specific response according to MDA criteria predicts immunotherapy efficacy among advanced non-small cell lung cancer (NSCLC) patients
2022
·
Andrea De Giglio
, Chiara Deiana
, et al.
·
Journal of Cancer Research and Clinical Oncology
·
12
Learning induced epigenetic modifications in the ventral striatum are necessary for long-term memory
2014
·
Davide Gaglio
, Fabrizio Capitano
, et al.
·
Behavioural Brain Research
·
10
Molecular Alterations and Pathways in Intrahepatic Cholangiocarcinoma: Available Evidence and New Perspectives
2025
·
Martina Astore
, Laura Fabbri
, et al.
·
International Journal of Molecular Sciences
·
9
PDF
PD-(L)1 Inhibitors as Single-Agent or in Combination with Chemotherapy for Advanced, PD-L1-high Non-Small Cell Lung Cancer: A Meta-Analysis
2021
·
Alessandro Di Federico
, Andrea De Giglio
, et al.
·
Future Oncology
·
9
Advanced non-small-cell lung cancer: how to manage non-oncogene disease
2022
·
Andrea De Giglio
, Alessandro Di Federico
, et al.
·
Drugs in Context
·
8
PDF
Improvements in Systemic Therapies for Advanced Malignant Mesothelioma
2023
·
Chiara Deiana
, Francesca Fabbri
, et al.
·
International Journal of Molecular Sciences
·
7
The prognostic role of body-mass index (BMI) for advanced EGFR positive non-small cell lung cancer (NSCLC) patients treated with osimertinib.
2021
·
Andrea De Giglio
, Alessandro Di Federico
, et al.
·
Journal of Clinical Oncology
·
3
Case Report: Long lasting response with TKI for combined hepatocellular-cholangiocarcinoma
2025
·
Chiara Deiana
, Andrea Palloni
, et al.
·
Frontiers in Oncology
·
2
IMpower 132: Is the Second Exception to the Rule No Longer an Exception?
2021
·
Alessandro Di Federico
, Giacomo Nuvola
, et al.
·
Journal of Thoracic Oncology
·
2
The protease inhibitor gabexate mesylate targets Raf kinase inhibitor protein and reverses epithelial–mesenchymal transition in triple-negative breast cancer cells
2026
·
Marzia Deserti
, Simone Sabbioni
, et al.
·
Frontiers in Oncology
·
1
PDF
Mutant p53 Associates with Human Equilibrative Nucleoside 1 Upregulation and Better Response to Adjuvant Gemcitabine in Intrahepatic Cholangiocarcinoma Patients
2025
·
Marzia Deserti
, Valeria Relli
, et al.
·
International Journal of Molecular Sciences
·
1
PDF
Stratifying Cardiovascular Risk in Patients With HCC Receiving Atezolizumab/Bevacizumab: A Comparison of ESC and CARDIOSOR Scores
2026
·
Bernardo Stefanini
, Lorenza Rimassa
, et al.
·
Liver International
PDF
Tare +/- chemotherapy in cholangiocarcinoma
2026
·
Deiana, Chiara
, Palloni, Andrea
, et al.
·
Zenodo (CERN European Organization for Nuclear Research)
Treatment Sequencing and Independent Outcomes of First- and Second-Line Chemotherapy in a Retrospective Series of Patients with Biliary Tract Cancer
2024
·
Giorgio Frega
, Andrea Palloni
, et al.
·
Journal of Clinical Medicine
113P Comparative efficacy and safety of PD-1/PD-L1 inhibitor monotherapy or in addition to chemotherapy for advanced, PD-L1 high non-small cell lung cancer (NSCLC): A meta-analysis of randomized trials
2021
·
A. Di Federico
, A. De Giglio
, et al.
·
Journal of Thoracic Oncology
PDF
Show more works
View as search
Works count:
18
Citation count:
247
H-index:
8
I10-index:
5
Year
Topic
Type